<DOC>
	<DOCNO>NCT00470041</DOCNO>
	<brief_summary>Description : To investigate bioavailability two anti-viral drug ( lamivudine zidovudine ) new oral formulation ( trial formulation ) especially design pediatric use . Interventions : 12 healthy volunteer receive cross-over design two formulation i.e . commercially available tablet formulation trial formulation . Blood sample ( 13 24 h ) take order determine pharmacokinetic profile drug formulation compare . Duration intervention : 2 day + 7 day wash-out oral administration .</brief_summary>
	<brief_title>Bioavailability Study New Pediatric Formulation Zidovudine/Lamivudine Adult Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Zidovudine</mesh_term>
	<mesh_term>Lamivudine</mesh_term>
	<mesh_term>Lamivudine , zidovudine drug combination</mesh_term>
	<mesh_term>Antiviral Agents</mesh_term>
	<criteria>Aged 18 55 year , extremes include . Males female . Smoking 10 cigarette , 2 cigar , 2 pipe per day ( nonsmoking ) least 3 month prior selection . Normal weight define Quetelet Index ( Body Mass Index ) 18 30 kg/m2 , extremes include . Subject competent willing sign inform consent form give detailed information study . Informed consent form sign voluntarily . Healthy basis pretrial physical examination , medical history , electrocardiogram result blood biochemistry haematology test urinalysis carry less 3 week first dose . Subjects present anaemia , neutropenia platelet deficits Subjects kidney failure renal dysfunction Pregnant , lactate female History allergy hypersensitivity Zidovudine Lamivudine . History clinically cardiovascular disease liver disorder</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>June 2010</verification_date>
	<keyword>Healthy volunteer</keyword>
</DOC>